The Blavatnik National Awards were founded in 2007 with the explicit goal of celebrating the potential of scientists at the beginning of their independent careers, a stage of academic life that often lacks the large-scale recognition reserved for senior figures. Each year, the program honors advances in three broad categories: life sciences, chemical sciences, and physical sciences and engineering. From this year’s cohort of 18 finalists, three laureates were selected, each receiving an unrestricted cash prize of $250,000. That figure makes the Blavatnik National Award the largest unrestricted scientific award in the United States for early-career scientists, meaning recipients can direct the money toward whatever research priorities they deem most promising rather than toward a funder-mandated project. Nagib earned the top honor in the chemical sciences category for his work enabling the faster discovery of better and longer-lasting pharmaceuticals.

For Nagib, the recognition is rooted in a research philosophy that has guided his laboratory since he joined Ohio State in 2014. His team develops new ways to create key medicinal building blocks by harnessing two classes of highly reactive chemical species: radicals and carbenes. Radicals are molecules or fragments that carry an unpaired electron, a structural feature that makes them extraordinarily reactive and therefore historically difficult to control in the precise, predictable way that pharmaceutical synthesis demands. Carbenes, meanwhile, are neutral species in which a carbon atom holds only two bonds and a lone pair, giving them the power to insert into other chemical bonds with remarkable efficiency. Both classes of reagents can accomplish transformations that conventional two-electron chemistry struggles to achieve, but taming them has long been a central challenge of synthetic methodology.

The practical motivation behind this work is the notoriously slow pace of pharmaceutical development. On average, it takes 10 to 15 years for a new medicine to travel from initial discovery to the market, a timeline shaped by the difficulty of designing molecules that are potent, selective, stable, and manufacturable at scale. Nagib’s methods attack this bottleneck directly by helping chemists create more potent and selective medicines faster, cheaper, and more efficiently. By giving synthetic chemists reliable new tools for constructing the molecular scaffolds on which drugs are built, his laboratory aims to compress the earliest and often most exploratory stages of the drug development pipeline, where promising candidates are identified and refined before the costly phases of testing and regulatory review begin.

Accessibility is a defining theme of the Nagib group’s approach. Rather than developing techniques that require rare equipment or specialized expertise, the laboratory has pursued chemistry that any researcher could, in principle, carry out. Nagib has described his dream for these advances as chemistry so simple that anyone in the world can do it without specialized techniques or strategies, and he has framed the group’s overarching goal as the democratization of radical chemistry so that it can be used by all, even within artificial intelligence workflows. That ambition reflects a broader shift in synthetic chemistry, where the value of a method is increasingly measured not only by what it can accomplish in an expert’s hands but by how easily it can be adopted, reproduced, and automated across the global research community.

Artificial intelligence has moved from the periphery to the center of that vision. Previously selected as a Blavatnik National Awards finalist in 2024, Nagib has since refocused a substantial portion of his research program on using machine learning to design new catalysts for drug candidates. One outcome of this effort is an open-source database that allows any researcher, even one working from a smartphone, to simulate chemical reactions and learn how to use radicals selectively. The implications of such tools are considerable. According to Nagib, chemical predictions that once would have taken more than a day to complete can now be accomplished in a few seconds, a speedup that changes the practical rhythm of research planning and lets chemists explore far larger regions of chemical space before committing laboratory time and materials to a synthesis.

Despite these dramatic gains in automation and predictive power, Nagib has been careful to emphasize that technology is a complement to human creativity rather than a substitute for it. He has argued that creativity does not come from sitting alone and having a sudden eureka moment, but instead emerges from constantly discussing new ideas, thinking carefully about why they did not pan out, and then coming up with new ones together. In his telling, the most exciting science lives at the edge of the possible, and the perseverance required to make such ideas actually work is the most rewarding part of the discovery process. That collaborative, iterative ethos is visible in the way his laboratory pairs computational prediction with hands-on experimentation, using each to inform and correct the other.

The scale of the competition underscores the significance of the honor. This year, 372 young scientists were nominated for the national awards, representing 187 academic and research institutions across 43 states and the District of Columbia. Finalists are selected by an independent jury of distinguished scientists, a process designed to insulate the evaluation from institutional influence and to reward genuine scientific impact. Since their founding in 2007, the Blavatnik Awards have invested more than $20 million in over 500 scientists worldwide, building a network of laureates and finalists whose work spans disciplines from structural biology to astrophysics. Nagib is being honored on Oct. 6 at the American Museum of Natural History in New York City during the 2026 Blavatnik Awards Gala ceremony, where the winning scientists will each give a short presentation about their research to an audience of peers, patrons, and science leaders.

Looking ahead, Nagib plans to put the monetary award to work immediately within his laboratory, directing the funds toward ongoing projects, the purchase of much-needed equipment and lab instruments, and the pursuit of other new ideas that the prize money makes feasible. Unrestricted awards of this kind are especially valuable for methodological chemistry, where the most speculative projects often struggle to attract conventional grant support before their feasibility is demonstrated. For Ohio State, the laureateship marks a milestone as the university’s first Blavatnik National Award, and for Nagib it serves as a signal from the broader scientific community. As he put it, the award mainly reflects how excited the community is about the work being done at Ohio State, and being recognized in this way motivates the team to keep chasing the stars, a fitting sentiment from a chemist whose career has been built on pursuing the reactive, unruly, and transformative corners of the molecular world.

Subject of Research: Radical and carbene chemistry methods for accelerating pharmaceutical discovery

Article Title: Ohio State professor named Blavatnik National Awards laureate

Article References: Ohio State professor named Blavatnik National Awards laureate. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: David Nagib, Blavatnik National Awards, Ohio State University, radical chemistry, carbenes, medicinal chemistry, drug discovery, artificial intelligence, catalyst design, open-source database, early-career scientists, chemical synthesis

The research, led by corresponding author Lei Zhang, Ph.D., a pharmaceutical engineering professor at Jining Medical University in China, addresses a problem that has long frustrated researchers who mine environmental DNA for drug leads. Microorganisms produce many of the natural products that have become important medicines, and the blueprints for making these compounds are written into their genomes as biosynthetic gene clusters, or BGCs — groups of neighboring genes that work together to produce a specific compound. In theory, sequencing the DNA of soil, ocean, or gut microbes should reveal an enormous trove of these clusters. In practice, the process rarely works that cleanly.

When researchers recover DNA directly from environmental samples — an approach known as metagenomics — the genetic material is typically shredded into short reads that must be assembled into longer contiguous sequences, or contigs. Because microbial genomes are complex and sequencing coverage is uneven, BGCs recovered from these metagenomic assemblies are often fragmented across multiple contigs. As Zhang explained, this fragmentation makes it difficult to reconstruct complete biosynthetic pathways and to determine which clusters are most likely to produce medically useful compounds. A gene cluster split across several disconnected fragments can look like genetic noise, and many potentially valuable pathways are discarded or overlooked as a result.

The strategy developed by Zhang and colleagues begins with a deceptively simple idea: use what is already known to find what is not. The researchers started with biosynthetic gene clusters whose products had already been experimentally characterized and used them as reference maps. They then searched large metagenomic datasets for related pieces of biosynthetic information. When those pieces turned out to be fragmented, the known clusters served as guides to help reconstruct the missing pathway and predict what kinds of molecules it might produce. In effect, the experimentally verified BGCs acted as templates that allowed the team to stitch scattered genetic fragments back into coherent biosynthetic narratives.

This guided reconstruction step is what distinguishes the approach from conventional genome mining, in which each fragment is typically analyzed in isolation. The researchers found that fragmented metagenomic data can contain valuable biosynthetic information that would be missed if every fragment were evaluated separately. By using known biosynthetic gene clusters as guides, they were able to piece together candidate pathways and identify potential bioactive products that no single contig could have revealed on its own. The method effectively converts partial, seemingly unusable genetic data into structured hypotheses about the chemistry of uncultured microbes.

Crucially, the team did not stop at computational prediction. To connect their in silico findings to measurable biology, they chemically synthesized selected predicted compounds and tested their biological activity in the laboratory. According to Zhang, this linkage of computational mining with experimental validation is a central feature of the work. The workflow identifies candidates for reconstruction, product prediction, chemical synthesis, and biological testing, creating a pipeline that moves a hypothesis from fragmented DNA sequence all the way to a molecule that can be pipetted onto living cells.

The experimental results provided an early proof of concept. The researchers chemically synthesized six candidate compounds and tested them across seven cancer cell lines. The compounds showed different patterns of cytotoxic activity, with compounds designated D and E displaying the most notable activity and clear differences emerging among the cancer cell lines. That variation matters: differential activity across cell lines suggests that the molecules interact with biological targets in specific ways rather than acting as indiscriminate toxins, which is a desirable starting point for any potential anticancer agent. The findings also demonstrate that compounds predicted from reconstructed metagenomic pathways can, once synthesized, exhibit genuine bioactivity.

The broader significance of the study lies in what it offers to the natural-products research community. Instead of treating partial BGCs as dead ends, the approach uses experimentally characterized clusters as guides for reconstruction and then focuses experimental resources on candidates that have a stronger basis for further study. In a field where the cost of synthesizing and testing every predicted compound would be prohibitive, this prioritization step is essential. It provides a route for turning incomplete or fragmented biosynthetic gene clusters into testable natural-product hypotheses, concentrating laboratory effort where the computational evidence is strongest.

At the same time, the researchers are careful to frame the limits of their method. Computational reconstruction and product prediction are prioritization steps, not endpoints. Chemical structures, biological activities, and therapeutic value must still be established through appropriate experiments, and further work is needed to confirm the biological mechanisms, activity profiles, and therapeutic potential of the six compounds evaluated. Zhang also noted that it remains to be shown whether the predicted products are actually produced naturally by the corresponding microorganisms — a question that matters both for understanding microbial ecology and for assessing whether these molecules could be sourced biologically rather than synthetically.

Even with those caveats, the study points toward a future in which the unculturable microbial majority becomes an accessible source of medicine rather than a permanent blind spot. As Zhang put it, fragmented metagenomic data should not simply be treated as incomplete or unusable; by using known biosynthetic pathways as guides, researchers can recover hidden biosynthetic information, prioritize promising natural-product candidates, and move them from computational prediction toward experimental testing. With antibiotic resistance rising and the pipeline for new anticancer agents in constant need of replenishment, practical methods for exploring the enormous chemical potential of environmental microbes could not arrive at a better time. The work suggests that the next generation of drugs may be hiding not in exotic organisms, but in the fragmented genetic data that laboratories around the world are already generating every day.

Subject of Research: Reconstruction of fragmented metagenomic biosynthetic gene clusters to discover natural-product drug candidates

Article Title: Mining fragmented data for antibiotics and cancer treatments

Article References: Mining fragmented data for antibiotics and cancer treatments. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: metagenomics, biosynthetic gene clusters, natural products, antibiotics, anticancer compounds, drug discovery, microbiology, chemical synthesis, cytotoxicity, uncultured microorganisms, genomic mining, Microbiology Spectrum

The motivation for the work stems from a simple but uncomfortable observation. Although AI-assisted synthesis planning has proliferated across the chemical and pharmaceutical industries in recent years, a detailed understanding of how and why these systems fail has never been achieved. According to the authors, current models still struggle with predicting less frequent yet strategically critical reactions, and they continue to produce hallucinated, incorrect predictions that are fundamentally misaligned with chemists’ expectations. For a discovery chemist weighing whether to trust a model’s suggestion, such failures are not merely inconvenient; they can derail weeks of planning and undermine confidence in computational tools altogether.

The core of the new system rests on two newly developed model components with what the researchers describe as complementary inductive biases. Inductive biases are the built-in assumptions a model makes about the structure of the problem it is learning, and in chemistry these assumptions matter enormously. One component may excel at capturing the local, rule-like transformations that dominate reaction databases, while another is better positioned to generalize to sparse, unusual reaction classes where such rules break down. By pairing architectures whose strengths and blind spots differ in a structured way, the team ensured that the ensemble’s errors would be less correlated than those of any single model.

Crucially, however, simply averaging predictions from different architectures is not enough, because the outputs of retrosynthesis models are discrete chemical transformations rather than continuous scores. The researchers therefore introduced a novel, learning-based ensembling strategy that integrates the diverse components. Rather than treating the ensemble as a post-hoc投票 mechanism, the approach learns how to weigh and combine candidate predictions in a way that reflects chemical validity and likelihood. This design allows RetroChimera to draw on the complementary knowledge embedded in each constituent model without letting the weaknesses of one corrupt the strengths of the other.

The experimental evaluation was deliberately broad, spanning several orders of magnitude in data scale, and the results point to robustness that previous systems lacked. RetroChimera outperformed leading baselines across the benchmark settings tested, and it demonstrated the ability to learn from very small numbers of examples per reaction class. This latter capability addresses one of the most persistent pain points in machine learning for chemistry: the long tail of the reaction literature. Highly unusual transformations, such as those used to forge complex molecular frameworks in natural product synthesis or to install challenging stereochemical motifs, are chronically underrepresented in public databases, yet they are often the exact steps that determine whether an ambitious synthesis route is feasible at all.

The team also subjected the model to tests of generalization outside its training data, a regime in which many deep learning systems collapse into confident nonsense. RetroChimera’s predictions remained reliable under distribution shift, suggesting that the combination of diverse inductive biases and learned ensembling confers a form of robustness that single-architecture models have not matched. The researchers frame this as a demonstration of the viability of deep learning for accurate synthesis prediction in increasingly challenging regimes, where the easy, well-documented reactions that dominate benchmarks are no longer representative of the problems chemists face.

Perhaps the most consequential validation, however, came not from automated benchmarks but from human experts. Using both pairwise and pointwise evaluation setups, the researchers asked organic chemists to compare RetroChimera’s predictions against published reference reactions and against the outputs of other AI models. In these blind assessments, the chemists systematically preferred the suggestions generated by RetroChimera. That preference for model output over the actual published record of real reactions is a striking result, because it indicates the system can propose transformations that experts judge more sensible or more practical than the routes that chemists historically chose and journals published.

To test whether these gains survive contact with industrial reality, the team performed zero-shot transfer and fine-tuning experiments on internal datasets from two major pharmaceutical companies. These proprietary datasets differ from public reaction corpora in both scale and character, reflecting the molecule types, reaction conditions, and strategic priorities of real drug discovery programs. RetroChimera showed robust generalization under this distribution shift, performing well without any additional training in the zero-shot setting and improving further when fine-tuned on internal data. For pharmaceutical companies that have long been skeptical of benchmarks built on public data alone, this industrial validation may prove as important as any academic result.

The collaboration itself reflects the interdisciplinary demands of the problem. The author list spans machine learning researchers specializing in molecular AI, computational chemists embedded in industrial research organizations, and practicing medicinal and synthetic chemists at GSK, Novartis, and other partner organizations. Equal contributions are credited to Krzysztof Maziarz, Guoqing Liu, and Felix Pultar of Microsoft Research AI for Science, with corresponding authorship shared with Marwin H. S. Segler, who has worked on AI-driven synthesis planning for nearly a decade. Representatives from GSK’s discovery sciences group in Stevenage and Wuppertal-based chemist Mario P. Wiesenfeldt round out a team designed to ensure that evaluation criteria mirrored the judgments of working chemists rather than proxy metrics alone.

Looking ahead, the work suggests a broader lesson for applying AI in the natural sciences: progress may depend less on scaling a single architecture than on deliberately designing and combining models with different, complementary biases. As chemical synthesis remains a critical bottleneck in the discovery and manufacture of functional small molecules, tools that align with expert intuition while generalizing beyond the training literature could reshape how new medicines, materials, and agrochemicals are planned. If systems like RetroChimera continue to earn the trust of the chemists who use them, the long-promised collaboration between artificial intelligence and synthetic chemistry may finally be moving from demonstration to daily practice.

Subject of Research: Chemist-aligned AI retrosynthesis planning using ensembles of diverse inductive bias models

Article Title: Chemist-aligned retrosynthesis by ensembling diverse inductive bias models

Article References: Maziarz, K., Liu, G., Pultar, F., Gardner, J., Gensch, T., Helie, J., Misztela, H., Tripp, A., Li, J., Kornev, A., Gaiński, P., Hoefling, H., Fortunato, M., Gupta, R., Baxter, A., Poole, D. L., Elward, J. M., Krzyzanowski, A., Pogány, P., … Segler, M. H. S. (2026). Chemist-aligned retrosynthesis by ensembling diverse inductive bias models. Nature. https://doi.org/10.1038/s41586-026-11160-9

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11160-9

Keywords: retrosynthesis, artificial intelligence, synthesis planning, machine learning, ensembles, inductive bias, chemical synthesis, pharmaceutical discovery, cheminformatics, deep learning, distribution shift, RetroChimera